Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GEMFIBROZIL

Form:

6 of 6 products shown

2 general benefit · 4 not a benefit

Other products in the same Health Canada class (C10A, C10AB) — coverage varies; not interchangeable

  • Bezafibrate (Bezalip): general benefit
  • Fenofibrate (Lipidil): general benefit, Not a benefit
  • Clofibrate (Atromid-S): not a benefit
  • Atorvastatin (Lipitor): general benefit
  • Cholestyramine resin (Questran Light 4g Pk): general benefit, Not a benefit
  • Colesevelam (Lodalis): general benefit, Listing status unconfirmed

9 more in the class list below

Teva-Gemfibrozil · DIN 02142074 · 600mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Gemfibrozil · DIN 02142074 Manufacturer: Teva Canada Limited; listing date 2008-02-12 Health Canada: Marketed since 2015-07-14 · brand TEVA-GEMFIBROZIL · ATC C10AB04 GEMFIBROZIL · form Tablet · route Oral · ingredients GEMFIBROZIL 600 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17230 · Verify on the e-Formulary ↗ (DIN 02142074)

Source record
DIN 02142074: Teva-Gemfibrozil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240600068; group id 305; item number 0668; lccId None; manufacturer id TEV Source form: Tab; strength: 600mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3982; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02142074 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17230
Interchangeable products
Apo-Gemfibrozil · DIN 01979582 · not recorded Lopid · DIN 00659606 · not recorded
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02142074
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Gemfibrozil · DIN 01979574 · 300mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.Discontinued 2024-07-21 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Gemfibrozil · DIN 01979574 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2024-07-21 · brand APO-GEMFIBROZIL CAP 300MG USP · ATC C10AB04 GEMFIBROZIL · form Capsule · route Oral · ingredients GEMFIBROZIL 300 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Gemfibrozil: Formulary list price $0.1340/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1340 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13840 · Verify on the e-Formulary ↗ (DIN 01979574)

Source record
DIN 01979574: Apo-Gemfibrozil Raw flags: chronicUseMed=Y, sec3=Y Item: 240600007; group id 305; item number 0667; lccId None; manufacturer id APX Source form: Cap; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1340; ministry $0.1340 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01979574 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13840
Interchangeable products
Lopid · DIN 00599026 · not recorded Teva-Gemfibrozil · DIN 02241704 · $0.1340
Shortage status: discontinued (2019-06-03, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01979574
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-07-21 — choose a marketed DIN from the same-category list.

Teva-Gemfibrozil · DIN 02241704 · 300mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-27 — choose a marketed DIN from the same-category list.Discontinued 2022-10-27 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-27 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-10-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Gemfibrozil · DIN 02241704 Manufacturer: Teva Canada Limited; listing date 2001-06-07 Health Canada: Cancelled post market since 2022-10-27 · brand TEVA-GEMFIBROZIL · ATC C10AB04 GEMFIBROZIL · form Capsule · route Oral · ingredients GEMFIBROZIL 300 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Gemfibrozil: Formulary list price $0.1340/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1340 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65364 · Verify on the e-Formulary ↗ (DIN 02241704)

Source record
DIN 02241704: Teva-Gemfibrozil Raw flags: chronicUseMed=Y, sec3=Y Item: 240600007; group id 305; item number 0667; lccId None; manufacturer id TEV Source form: Cap; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1340; ministry $0.1340 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241704 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65364
Interchangeable products
Apo-Gemfibrozil · DIN 01979574 · $0.1340 Lopid · DIN 00599026 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241704
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-10-27 — choose a marketed DIN from the same-category list.

Lopid · DIN 00599026 · 300mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.Discontinued 2013-07-18 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lopid · DIN 00599026 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2013-07-18 · brand LOPID CAP 300MG · ATC C10AB04 GEMFIBROZIL · form Capsule · route Oral · ingredients GEMFIBROZIL 300 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lopid: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5759 · Verify on the e-Formulary ↗ (DIN 00599026)

Source record
DIN 00599026: Lopid Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240600007; group id 305; item number 0667; lccId None; manufacturer id PFI Source form: Cap; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00599026 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5759
Interchangeable products
Apo-Gemfibrozil · DIN 01979574 · $0.1340 Teva-Gemfibrozil · DIN 02241704 · $0.1340
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00599026
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.

Apo-Gemfibrozil · DIN 01979582 · 600mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.Discontinued 2024-07-31 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Gemfibrozil · DIN 01979582 Manufacturer: Apotex Inc.; listing date 2008-02-12 Health Canada: Cancelled post market since 2024-07-31 · brand APO-GEMFIBROZIL · ATC C10AB04 GEMFIBROZIL · form Tablet · route Oral · ingredients GEMFIBROZIL 600 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13841 · Verify on the e-Formulary ↗ (DIN 01979582)

Source record
DIN 01979582: Apo-Gemfibrozil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240600068; group id 305; item number 0668; lccId None; manufacturer id APX Source form: Tab; strength: 600mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7520; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01979582 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13841
Interchangeable products
Lopid · DIN 00659606 · not recorded Teva-Gemfibrozil · DIN 02142074 · not recorded
Shortage status: resolved shortage (ended 2019-05-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01979582
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-07-31 — choose a marketed DIN from the same-category list.

Lopid · DIN 00659606 · 600mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.Discontinued 2013-07-18 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lopid · DIN 00659606 Manufacturer: Pfizer Canada Inc.; listing date 2008-02-12 Health Canada: Cancelled post market since 2013-07-18 · brand LOPID 600MG · ATC C10AB04 GEMFIBROZIL · form Tablet · route Oral · ingredients GEMFIBROZIL 600 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lopid: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9259 · Verify on the e-Formulary ↗ (DIN 00659606)

Source record
DIN 00659606: Lopid Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240600068; group id 305; item number 0668; lccId None; manufacturer id PFI Source form: Tab; strength: 600mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00659606 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9259
Interchangeable products
Apo-Gemfibrozil · DIN 01979582 · not recorded Teva-Gemfibrozil · DIN 02142074 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00659606
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

CLOFIBRATE

· 2 products · Listed, not a benefit · strengths: 500mg · Cap

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TEVA-GEMFIBROZIL (gemfibrozil tablet) is indicated in adults as an adjunct to diet and other therapeutic measures for: • Treatment of patients with very high serum triglyceride levels, Fredrickson classification Type IV and V hyperlipidemias, who are at high risk of sequelae and complications (i.e. pancreatitis) from their hyperlipidemia. • Treatment of patients with hypercholesterolemia, Type IIa and IIb mixed dyslipidemias, to regulate lipid levels (reduce serum triglycerides and LDL cholesterol levels and increase HDL cholesterol). TEVA-GEMFIBROZIL alone may not be adequate therapy in some patients with familial combined hyperlipidemia with Type IIb and IV hyperlipoproteinemia. Initial therapy for hyperlipidemia should include a specific diet, weight reduction, and an exercise program and for patients with diabetes mellitus, a good diabetic control. Gemfibrozil is not indicated for the treatment of Type I hyperlipoproteinemia. 1.1 Pediatrics Pediatrics (0 to >18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics No data is available. https://pdf.hres.ca/dpd_pm/00072920.PDF PM date: November 25, 1994 Source product: TEVA-GEMFIBROZIL; DIN 02142074; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Gemfibrozil · DIN 02142074 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02142074

Check this DIN again

Apo-Gemfibrozil · DIN 01979574 Shortage status: discontinued (2019-06-03, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01979574

Check this DIN again

Other review policies

For Teva-Gemfibrozil, Lopid, Apo-Gemfibrozil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026